ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
March 31 2021 - 6:33AM
Business Wire
ChromaDex External Research Program (CERP) and the Citrin
Foundation to collaborate on series of studies exploring rare
disease citrullinemia
ChromaDex Corp. (NASDAQ: CDXC) today announced a new research
initiative with the Citrin Foundation of Singapore to study the
effects of Niagen® nicotinamide riboside (NR) and citrin
deficiency, a rare genetic condition. In collaboration with the
ChromaDex External Research Program (CERP™) and leading research
institutions, the Citrin Foundation will fund a series of
preclinical and clinical studies to explore the potential impact of
increased NAD+ levels on patients with citrin deficiency. The first
study, led by Prof. Paul M. Yen and other scientists at Duke-NUS
Medical School in Singapore, will examine the ability of NR to
impact mitochondrial function, lipid accumulation, inflammation,
and fibrosis in the liver using preclinical models of citrin
deficiency.
“Citrin deficiency impairs mitochondrial function and disrupts
the NAD+ system, leading to adverse effects on tissues such as the
liver,” says Professor Sir John Walker, Nobel Laureate and Emeritus
Director, MRC Mitochondrial Biology Unit in the University of
Cambridge, England, and member of the ChromaDex Scientific Advisory
Board (SAB). “Although there is as yet no cure for this genetic
condition, understanding whether and to what extent augmenting
cellular NAD+ levels may offset the impaired mitochondrial function
are important research questions to address.”
Citrin deficiency is a rare genetic condition that may cause
increased levels of ammonia in the blood under certain
circumstances. This rare genetic condition could be
life-threatening without proper diagnosis and diet management. It
could most commonly cause neonatal cholestasis in newborns, failure
to thrive in children or in relatively rare instances, CTLN2, its
most severe form, later in life, causing a host of neurological
problems, hyperlipidemia, and severely impaired liver function.
NAD+ levels are implicated in the proper function of metabolically
active cells and tissues. This new research collaboration will
deepen the understanding of NAD+ and citrin deficiency.
“The Foundation is committed to providing support at the
foundational research level as well as support for patients and
their families,” says Citrin Foundation co-founder Barbara Yu. “We
are proud to work with the scientific innovators at ChromaDex and
researchers at leading institutions around the world to find more
answers to this life-threatening condition.”
“We are very excited to work together with ChromaDex and the
Citrin Foundation to understand the role of NAD+ in citrin
deficiency. We hope that our research will not only lead to better
understanding and treatment of citrin deficiency, but also other
genetic mitochondrial disorders and non-alcoholic fatty liver
disease,” says Prof. Paul M. Yen from Duke-NUS Medical School.
For additional information about ChromaDex, please visit
www.chromadex.com.
For additional information on the Citrin Foundation, please
visit www.citrinfoundation.org.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended including statements related to the role NAD+ may play in
Citrin deficiency and the ability of NR to impact mitochondrial
function, lipid accumulation, inflammation, and fibrosis in the
liver using preclinical models of Citrin deficiency. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects," "anticipates,"
"intends," "estimates," "plans," "potential," "possible,"
"probable," "believes," "seeks," "may," "will," "should," "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2020, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210331005177/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024